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Therapy of cutaneous leishmaniasis 
Samuel A. Lee(1,2) and Rodrigo Hasbun c3) 
There have been many treatment modalities used for the therapy of cutaneous leishmaniasis. Although treatment 
need not be given for cosmetically insignificant lesions, which are often self-limited, therapy is usually indicated for 
larger, cosmetically significant and disfiguring lesions, and lesions which progress. This review summarizes the published 
evidence in support of the numerous therapeutic options that have been employed for cutaneous leishmaniasis. 
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INTRODUCTION 
Leishmania species are protozoa1 parasites of the order 
Kinetoplastida, which give rise to a number of distinct 
clinical syndromes, ranging from self-limited cutaneous 
lesions to progressive visceral disease and death. There 
have been more than 20 species identified, most of which 
cause zoonotic infections, but which can also cause 
disease in humans in endemic areas. Numerous rodent 
and canine species serve as reservoirs, and sandflies 
serve as vectors. Rare cases of congenital or transfusion- 
related transmission have also been reported. Cutaneous 
leishmaniasis is classified into two different clinical syn- 
dromes: New World if it is acquired in the Americas, and 
Old World if it is acquired in Africa, Asia, the Middle 
East, or Europe. This discussion will focus on reviewing 
the clinical evidence supporting various options for the 
treatment of cutaneous leishmaniasis (CL), particularly 
the Old World form. 
Epidemiology 
Over 350 million people live in endemic areas, and 
the WHO has estimated the prevalence of CL to be 
12 million cases/year and that of CL to be 1.5-2.0 million 
cases/year, although the true prevalence and incidence 
may be considerably higher, due to underrep0rting.l 
Old World CL is usually due to L. major, L. tropica, 
or L. aethiopica? New World CL is usually caused by 
members of the L. mexicana complex (L. mexicana 
mexicana, L. mexicana amazonensis, L. mexicana 
venezuelensis), and New World mucocutaneous leish- 
maniasis is usually caused by members of the L. 
bvaziliensis complex (L. braziliensis braziliensis, L. 
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bvaziliensis panamensis, and L. braziliensis guyanensis) 
(Table 1). 
CL is usually sporadic in nature, but can occasionally 
occur in an epidemic pattern, e.g. when large groups of 
susceptible persons migrate to an endemic area (i.e. 
military personnel). Old World CL due to L. major is 
found in rural desert areas of central Asia, the Middle 
East, and northern Africa. It causes lesions that tend 
to be large and ‘wet’ in appearance. The primary 
reservoir consists of desert rodents. Old World CL due 
to L. tropica is endemic to urban areas of the Middle 
East, the Mediterranean, India, Pakistan, and central 
Asia. The lesions tend to be ‘dry’, with a central crust. 
Old World CL caused by L. aethiopica is found in the 
Ethiopian highlands and Kenya, where it causes both 
simple CL and diffuse CL. 
Pathogenesis 
Leishmanial infections are transmitted via the bite of 
infected female sandflies of the genera Phlebotomus, 
Lutzomyia, or Psychodopygus. The parasite lives as an 
extracellular, flagellated promastigote in the gut of the 
insect. After multiplication and differentiation in the 
sandfly gut, approximately 1 week later the infectious 
promastigotes migrate to the proboscis. Following 
inoculation into the skin of a mammalian host, the 
parasite exists within lysosomes of mononuclear 
phagocytes as an intracellular amastigote, characterized 
by a large eccentric nucleus and a mitochondrial 
structure called a kinetoplast.The clinical and histologic 
appearance of the CL skin lesions is related to an 
interaction between the host’s immune response and the 
virulence factors of the different Leishmania species. 
The clinical spectrum of CL ranges from an entity called 
diffuse CL, where there is a scarce immune response 
and heavily parasitized macrophages, to leishmaniasis 
recidivans, where there is a strong mononuclear cell 
response, with few amastigotes. 
Clinical features 
Thus, CL presents as a spectrum of disease ranging from 
single, chronic ulcerative lesions (‘oriental sores’) to 
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Table 1. Leishmaniasis: clinical syndromes and geographic distribution 
Syndrome Most common species Distribution 
Cutaneous leishmaniasis 
Old World L. major 
New World 
Mucocutaneous leishmaniasis 
(espundia) 
Visceral leishmaniasis 
L. tropica 
L. aethiopica 
L. mexicana 
L. braziliensis 
L. chagasi 
L. peruviana 
L. panamensis 
L. venezuelensis 
L. braziliensis 
L. donovani 
L. chagasi 
L. amazonensis 
Rural desert areas of 
Asia, Middle East, and 
northern Africa 
Urban areas of Middle East, 
Mediterranean, India, Pakistan, 
and central Asia. 
Ethiopian highlands, Yemen, 
and Kenya 
Central and South America 
America 
Peru, Argentina 
Panama, Costa Rica, Colombia 
Venezuela 
Central and South America 
India, China, Nepal, Pakistan, 
East Africa 
Latin America 
Brazil 
disseminated nodular lesions (‘diffuse’ CL). The typical 
lesion appears as an erythematous papule at the site of 
inoculation which increases in size and ulcerates. The 
lesions are round with a raised border. Wet lesions are 
covered with an exudate, and may become secondarily 
infected with bacteria or fungi. Other lesions are dry 
with central crusting. Old World CL is frequently self- 
limited, eventually resolving without treatment. However, 
scarring associated with the lesions is difficult to predict 
on initial presentation, and can be disfiguring, parti- 
cularly in Old World CL. 
There are two forms of chronic CL: diffuse CL 
and leishmaniasis recidivans. Diffuse CL is rare, and 
is associated with L. aethiopica, L. arnazonensis, 
L. mexicana, and other minor species. In this condition, 
there is an absence of cellular immune responses, and 
heavily parasitized macrophages are abundant in the 
dermis. The cutaneous lesion begins as a non-ulcerative 
papule, followed by migration of the organisms to other 
sites, resulting in disseminated nodules. Areas of 
involvement can be extensive, and the lesions could be 
permanent. Leishmaniasis recidivans is a relapsing form 
of CL caused by L. tropica, and is seen mostly in Iran 
and central Asia. There is an intense cellular immune 
response to Leishmania antigen; on skin biopsy, a dense 
mononuclear infiltration with few amastigotes is seen. 
It usually affects the face, and it can last for several 
decades. 
HIV co-infection with Leishmania species can alter 
the epidemiology, diagnosis, and response to therapy.3 
Visceral leishmaniasis is an important opportunistic 
infection in patients with HIV/AIDS, and cutaneous 
leishmaniasis can present atypically with multiple 
cutaneous lesions and mucosal involvement.4 Con- 
ventional therapy in patients with HIV/AIDS and 
leishmaniasis is associated with a higher relapse rate, 
and therefore secondary prophylaxis is recommended.5 
Diagnosis 
The diagnosis of CL is confirmed by identification 
of amastigotes in tissue or culture of promastigotes. 
The two most common media utilized in culture are a 
modified Novy-MacNeal-Nicolle medium (NNN) and 
Schneider’s Drosophila medium enriched with fetal calf 
serum. Growth of most organisms occurs within 
l-2 weeks, although cultures should be maintained for 
4 weeks. Demonstration of parasites in the skin can 
be accomplished by slit-incision along the ulcer edge, 
whereby exposed tissue and fluid are scraped onto a 
slide or culture medium. Skin biopsy by a standard 
punch biopsy can also be done at the most inflamed 
edge of a lesion. Giemsa staining allows the best visual- 
ization of the parasite. 
Speciation is usually only available from research 
laboratories, the Centers for Disease Control (Atlanta, 
USA), or the European reference center in Montpelier, 
France. Methods of speciation include isoenzyme 
analysis, kinetoplast DNA hybridization, and use of 
monoclonal antibody detection. Serologic testing is 
of limited utility in CL. Intradermal skin testing 
(Montenegro test) using killed Leishmania antigens can 
be of utility in some cases, and is available through the 
WHO. The sensitivity of Leishmania skin testing is high, 
but in endemic areas it lacks specificity, because it does 
not distinguish between current and past infections.6 
Because of the difficulties with current diagnostic 
strategies, recent studies have focused on the develop- 
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ment of polymerase chain reaction (PCR) methods for 
the diagnosis of leishmaniasis by amplification and 
detection of ribosomal or kinetoplast target DNA.6,7 
Weigle et al6 compared a PCR method for detection 
of kinetoplast DNA in biopsy specimens with three 
conventional diagnostic methods, and found, in 255 
patients with acute CL lesions, that the sensitivity of 
PCR (75.7%) was significantly better than that of 
Giemsa-stained lesion scrapings (46.7%), biopsy culture 
(.55.3%), and aspirate culture (46.3%), and all three 
conventional methods combined (70.2%). 
Overview of treatment modalities 
The decision on whether to treat CL depends on the 
location and extent of the lesion, and whether mucosal 
leishmaniasis is a possibility. However, if the lesion is in 
a cosmetically unacceptable area or is not healing, 
specific treatment is indicated. An incredibly diverse 
array of therapeutic agents has been tried for the 
treatment of CL, in part due to the geographic and 
clinical diversity of leishmaniasis, the lack of a com- 
pletely reliable mode of treatment, often with significant 
side effects, and a paucity of rigorous clinical trials 
studying these agents.8-11 The pentavalent antimony (Sb) 
compounds sodium stibogluconate (Pentostam, Glaxo- 
Wellcome, Research Triangle Park, North Carolina, USA) 
and meglumine antimoniate (Glucantime, Rhone- 
Poulenc, Paris, France) remain the mainstay of therapy 
for most forms of leishmaniasis. Other major treatments 
use physical modalities (heat, cryosurgery), local or 
intralesional injections, various anti-infective agents 
(Dapsone, metronidazole, trimethoprim-sulfamethox- 
azole), amphotericin B, pentamidine, allopurinol, azoles, 
immunotherapy (i.e. interferon-y), and a variety of 
miscellaneous agents. 
Pentavalent antimony (Sb) 
Sodium stibogluconate is available in the USA from the 
CDC (telephone: 404-639-3670, business hours, 404-639- 
2888, non-business hours) through an investigational 
drug protocol. It is also available in Europe, Africa, and 
India. Meglumine antimoniate is used in Latin America 
and in French-speaking countries in Africa. There is 
extensive experience in the use of Sb in the treatment of 
leishmaniasis, although it is not clear how comparable in 
terms of efficacy and toxicity the different formulations 
are. In the only study to compare sodium stibogluconate 
and meglumine antimoniate for the treatment of CL, 
Deps et all2 conducted a single-blind, randomized study 
of 63 patients with localized CL, and found that efficacy 
was similar but hepatic and pancreatic toxicity was 
higher in the sodium stibogluconate arm. However, the 
preparation of sodium stibogluconate used in this study 
may have been unusually toxic. 
Sb has had variable success in the treatment of Old 
World CL, and because the disease is often self-limited, 
Sb can be avoided in many circumstances. Thus, few 
studies have been done specifically with Sb and Old 
World CL. Chulay et ali3 used high-dose Sb at 
18-20 mg/kg twice daily for the treatment of three 
patients with CL caused by L. aethiopica in Kenya, 
which usually responds poorly to conventional dosing 
with Sb. All patients had a good long-term response. 
Belazzoug et al I4 treated approximately 400 school 
children in Algeria with Sb (given intramuscularly) 
or placebo, and found no significant differences in 
response rates (48% versus 55% respectively). Few 
details, however, were included in the publication. 
El-Safi et alI5 reported their experiences with the 
treatment of CL, giving approximately 110 patients 
Sb (600 mg/day for 21-30 days), and achieving clinical 
cure in all but two patients. 
The recommended dose of Sb is 20 mgikg per 
day for 20 days (for CL) or 28 days (for visceral 
leishmaniasis). Important side effects include cardio- 
toxicity (prolongation of QT,, ST-T wave changes), 
biochemical and, less commonly, clinical pancreatitis, 
arthralgias, myalgias, nausea/vomiting, liver transaminase 
abnormalities, pancytopenia, and, rarely, renal toxicity. 
Gasser et all6 reported a small prospective study of 17 
patients treated with Sb for CL, in which 16 patients 
developed an increase in pancreatic enzymes and 12 
developed clinical pancreatitis, although pancreatitis 
resolved with discontinuation of therapy. 
Local heat or cold therapy 
Junaid17 reported his experience of treating 178 patients 
with CL in Iraq using a heat-generating device creating 
a temperature of 55°C for 5 min. One hundred and sixty- 
two patients responded well to a single application of 
heat. Aram and Leibovici18 used local hyperthermia to 
42°C for 2-3 min induced by ultrasound to treat 18 
patients with CL in Israel. Twenty-two lesions (78.5%) 
in 13 patients resolved completely over 5-10 weeks. 
Both of these uncontrolled studies reported minimal 
side effects. Navin et all9 conducted a randomized trial 
of 66 patients in Guatemala with proven New World 
CL divided into three treatment arms: meglumine 
antimoniate (850 mg/day for 15’ days), localized heat 
from a radiofrequency generator (50°C for 30 s, three 
weekly treatments), and placebo. Cure rates were 16 
(73%) 16 (73%), and 6 (27%), respectively. Velasco- 
Castrejon et alzO treated 201 patients with CL in Mexico 
with heat therapy. A localized current field-radio- 
frequency device was used to give a single application 
of heat at 50°C for 30 s. Of 191 patients evaluated at 
8 weeks of follow-up, 172 (90%) were cured. 
Bassiouny et alzl used a CO2 cryomachine to treat 
30 patients with histologically confirmed CL in Egypt 
in an uncontrolled trial, reporting that all patients 
were cured without scarring at 4-5 weeks. Applications 
generally lasted for 30-60 s, and most cases resolved 
with a single treatment. Serial biopsies confirmed killing 
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of the parasite. Leibovici and Aram treated 14 patients 
with confirmed CL in Israel with liquid nitrogen in an 
uncontrolled study. All lesions were cured clinically and 
parasitologically at 3-8 weeks, without scarring or 
relapse at 4 months. Despite these promising results, in 
a larger, unblinded trial, Al-Gindan et a123 treated 88 
patients with cryosurgery but achieved a cure rate of 
only 27%, as compared to 41% with Sb and 30% with 
ketoconazole. Side effects included hypopigmentation, 
and some patients developed satellite lesions. 
El Darouti and Rubaie24 compared cryotherapy, 
intralesional Sb and combined cryotherapy and 
intralesional Sb in a total of 44 patients in an unblinded 
study in the United Arab Emirates. The combination 
therapy group achieved a 100% cure rate at 6 weeks, 
compared to 68% in the cryotherapy group, and 44% in 
the intralesional Sb group. 
Topical and intralesional therapies 
Paromomycin ointment has been studied by several 
groups in the treatment of Old World CL, as a topical 
preparation of low toxicity. However, some paromomycin 
ointments are formulated with dimethylsulfoxide 
(DMSO), h’ h w ic is a potentially toxic irritant. El-Safi et 
a125 performed a double-blind study comparing lo-day 
courses of paromomycin (16 patients) and placebo (15 
patients), and found no significant difference in the 
response rates, although when individual lesions 
were compared, a significant difference was found. 
El-On et a12’j compared paromomycin and 15% 
methylbenzethonium chloride (MBCl), paromomycin 
and 12% MBCl, and placebo, in a randomized, double- 
blind, crossover study in 39 patients. Both treatment 
arms had a combined cure rate of 74.2% versus 26.6% 
in the placebo group. No difference was found between 
the two treatment arms. Two more recent randomized, 
placebo-controlled trials of paromomycin in Old World 
CL have not had similar success. In a study by Ben 
Salah et a1,27 115 patients with confirmed CL due to 
L. major in Tunisia were randomized to paromomycin 
ointment (57) or placebo (58) for 2 weeks. There was 
no difference in adverse effects. Although there was a 
trend for parasitologic improvement (negative smears) 
at day 15, this difference was not apparent at days 45 and 
105. 
In a study by Asilian et a1,28 251 patients with CL 
were randomized to paromomycin ointment (125) 
or placebo (125) for 2 weeks. Paromomycin ointment 
was well tolerated. Although at days 15 and 105 (but 
not at day 45) there was parasitologic improvement 
in the treatment group, no clear clinical benefit was 
observed. 
Larbi et a129 performed a randomized, double-blind 
study of topical clotrimazole versus miconazole for 
30 days for the treatment of CL in 54 patients (151 
lesions) in Saudi Arabia. Of 89 lesions treated with 
clotrimazole, 15.7% healed fully, and 47.2% were reduced 
in size, versus 0.0% and 35.5% in the miconazole group. 
No significant side effects were observed. 
In vitro experiments have demonstrated the para- 
tidal activity of nitric oxide against Leishmania.30 Nitric 
oxide is synthesized in macrophages, and diffuses 
well into skin tissues. S-nitroso-N-acetylpenicillamine 
(SNAP) is a compound that generates the production of 
nitric oxide. Lopez-Jaramillo et a131 used SNAP cream 
every 4 h while the patients were awake for 10 days for 
the treatment of 16 patients with CL in Ecuador. At 30- 
day follow-up, all lesions were healed and new skin 
was observed. In contrast, Davidson et a132 treated 42 
patients with CL with a topical cream that induces the 
generation of nitric oxide. In this approach, nitric oxide 
is generated non-enzymatically by the acidification of 
nitrite (KN02) by ascorbic acid or salicylic acid. Only 11 
(28%) patients showed clinical improvement, and only 
5 (12%) were cured at 2 months. 
Soto et a133 used a combined regimen of topical 
paromomycin (15%) and MBCl (12%) twice a day for 
10 days plus intramuscular or intravenous meglumine 
antimoniate for 3 or 7 days in Colombian patients with 
CL. In the cohort of 20 patients who received the 
injectable meglumine, the cure rate was 90% versus 
42% in those who received it for only 3 days. 
Intralesional treatment of CL with Sb has been 
used to minimize the systemic effects of the medication. 
Faris et a134 conducted an uncontrolled study using 
intralesional Pentostam in 710 patients with confirmed 
CL in Saudi Arabia. Most lesions required eight 
injections for resolution, although some required up to 
24 injections. Seventy-two per cent of lesions were 
cured, 23.9% improved, and 4.1% worsened. Side effects 
were limited to pain at the injection site and hyper- 
pigmentation. 
Tallab et a135 conducted a prospective dose-ranging 
study of 96 patients (129 lesions) with confirmed CL in 
Saudi Arabia with intralesional Sb. Their results suggest 
that alternate-day or weekly injections of Sb for a 
total of three injections was more effective than daily 
injection. The final complete cure rate was 99.2% after 
additional injections were given. Good results with 
intralesional Sb have also been obtained in New World 
CL.36 
Cohen and Livshin37 treated a total of 50 CL lesions 
in 31 patients with intralesional injections of emetine 
hydrochloride, and obtained a cure rate of 100%. The 
injections were administered weekly or bi-weekly, and 
the amount of emetine injected varied from 10 to 
160 mg, depending on the size of the lesion. 
Anti-infective agents 
Several conventional anti-infective agents have been 
tried for the treatment of CL, including dapsone, 
rifampin with or without isoniazid, metronidazole, and 
trimethoprim-sulfamethoxazole (TMP-SMX). Dogra 
et a138 conducted the first study of dapsone (50 patients) 
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versus an untreated control group (15 patients) in India. 
Forty of 50 patients in the treatment group were 
clinically cured after 21 days of treatment, and no 
clinical improvement was seen in any members of the 
control group.The only side effect from the dapsone was 
nausea (14%). Following this, Dogra39 conducted a 
double-blind study of 120 patients, comparing oral 
dapsone (60 patients) or placebo (60 patients) for 
6 weeks. Of the patients receiving dapsone, 49/60 (82%) 
were cured. Side effects included nausea (nine patients) 
and anemia (three patients). In the placebo group, O/60 
showed spontaneous healing in the 6-week study period. 
Rifampin has shown some efficacy in the treatment 
of CL, with or without isoniazid. Livshin et a140 
compared rifampin alone to rifampin with isoniazid in 
39 patients with CL in Israel. The duration of therapy 
varied from 14 to 60 days. At both 1 and 2 months 
after beginning therapy, no major difference was found 
between the two groups (52.9% versus 55%, respec- 
tively). Other studies have shown variable success rates 
with rifampin, ranging from 0% to 80%. 
There are various case reports and case series 
describing the use of metronidazole and TMP-SMX for 
the treatment of CL with variable success.r” 
Amphotericin B 
Amphotericin has been used since its introduction into 
clinical medicine in 1955 as an alternative to Sb, with 
high cure rates, but significant toxicities.li Although it is 
considered an effective alternative to Sb, there is a 
paucity of published trials regarding its use in CL. 
Liposomal formulations of amphotericin have demon- 
strated in vitro efficacy against experimental CL in 
mice,41 and several case reports have described its 
successful use in leishmaniasis. 
Pentamidine 
Pentamidine has also proven to be efficacious in the 
treatment of leishmaniasis, including Old World CL.8 
Like amphotericin B, it is considered a traditional 
alternative to Sb, but its use is limited by its toxicities. 
Soto-Mancipe et a142 randomized 92 patients with 
New World CL to four treatment arms: intramuscular 
meglumine antimoniate (10 mg/kg b.i.d. for 20 days), 
intramuscular pentamidine (2 mgikg q.o.d. in seven 
doses), oral itraconazole (200 mg b.i.d. for 28 days), or 
no treatment. Cure rates were as follows: meglumine 
antimoniate 21/23 (91%), pentamidine 23/24 (96%), 
itraconazole approximately 25 %, and placebo 14/22 
(36%, not including six patients lost to follow-up). A side 
arm of the study assessed intramuscular pentamidine at 
a lower dose (2 mg/kg q.o.d. in four doses), reporting 
cure in 14/19 patients (74%). The results of this study 
were difficult to interpret, due to a relatively high 
number of patients lost to follow-up or violating the 
treatment protocol. 
Allopurinol 
Allopurinol is metabolized to toxic nucleosides by 
the Leishmania parasite. Martinez and Marr43 con- 
ducted an open-label, randomized study of 110 patients, 
comparing allopurinol plus meglumine antimoniate 
versus meglumine alone in New World CL in Colombia. 
All patients had proven L. braziliensis panamensis 
infection. Allopurinol was given at 20 mg/kg per day 
in four divided doses for 15 days; meglumine was 
administered at 20 mg/kg for 1.5 days. Cure rates were 
as follows: meglumine alone 36%, allopurinol and 
meglumine 74%, allopurinol alone 80%, and untreated 
0%. No major toxic effects were observed. 
These results must be interpreted with caution, 
however, as there was an unusually low cure rate in the 
group treated with Sb alone.44 Velez et a145 conducted 
a randomized, partially double-blind, controlled trial 
using allopurinol alone to treat CL in Colombia, 
enrolling 187 patients. Patients were randomly assigned 
to receive either allopurinol(20 mg/kg q.d. for 28 days), 
placebo tablets (for 28 days), or intramuscular glucantime 
(20 mglkgiday for 20 days). One hundred and fifty-seven 
patients (86%) were evaluated. Cure rates were as 
follows: allopurinol ?8/55 (33%) placebo 17146 (37%) 
and glucantime 52156 (93%). No significant difference 
was found between the allopurinol and placebo groups. 
The use of allopurinol in combination with Sb 
has also been specifically addressed. Momeni and 
Aminjavaheri46 conducted an uncontrolled trial of 
allopurinol and meglumine antimoniate in 25 patients 
with recurrent CL unresponsive to previous therapy, and 
a duration of disease greater than 2 years. Twenty-four 
of 25 patients responded well to treatment, and no 
relapse occurred at l-year follow-up. No significant side 
effects were noted. Martinez et a147 conducted an open- 
label, randomized, controlled study in Colombia in 100 
patients, comparing stibogluconate (49 patients) versus 
stibogluconate and allopurinol (51 patients) in the 
treatment of CL. Cure rates were 39% for Sb, and 71% 
for Sb and allopurinol, which was statistically significant. 
Azoles 
Azoles interfere with leishmanial cell membrane 
biosynthesis. Ketoconazole has been used in the treat- 
ment of Old World CL, with mixed results. Weinrauch 
et a148 report treating approximately 100 patients with 
CL in Israel, with a cure rate of approximately 70% in 
cases due to L. major after 4-6 weeks of treatment with 
200-400 mg of ketoconazole. Results were poor in cases 
of CL due to L. tropica or L. aethiopica. Ketoconazole 
has been used with success in New World CL as well. 
Saenz et a149 obtained comparable cure rates in a small 
study comparing ketoconazole and Pentostam (16/21 
versus 13/19, respectively). In a larger study, Navin 
et a150 randomized 120 patients to ketoconazole (600 mg 
q.d. for 28 days), Pentostam, and placebo. Treatment 
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outcome depended on the particular species involved. 
For L. braziliensis, response rates were 24125 for Sb, and 
7/23 for ketoconazole. For L. mexicana, response rates 
were 417 for Sb, and 8/9 for ketoconazole. 
Singh et a151 reported poor results in a small trial 
involving 16 patients with CL in India. Patients were 
given ketoconazole at 200 mg b.i.d. for 10 weeks. Of 14 
patients completing the study, no patients showed any 
improvement. Alsaleh et al52 compared dosages of 
ketoconazole in the treatment of CL in Kuwait. 
Eighteen patients received 600 mg and 15 patients 
received 800 mg of ketoconazole daily, with cure rates of 
12/15 (80%) and 9/11(82%), respectively, inpatients com- 
pleting the study, and minimal side effects. Ozgoztasi 
and Baydar53 compared topical paromomycin and oral 
ketoconazole in Turkey in an open-label, randomized 
study enrolling 72 patients. Cure rates were 15/40 (37.5%) 
in the paromomycin group and O/32 (0.0%) in the 
ketoconazole group. 
Itraconazole has shown promising results in several 
earlier case reports54 and small pilot studies.55-57 
Momeni et als8 conducted a randomized, double-blind 
study comparing itraconazole (7 mg/kg/day) and placebo 
for 3 weeks in the treatment of CL in Iran. One hundred 
and forty patients were enrolled, and 131 patients 
completed treatment, from an area endemic for 
L. major. Cure rates were 59% in the itraconazole 
group, and 44.3% in the placebo group, although 
statistical significance was not achieved. No difference 
was found in adverse effects. 
Terbinafine 
Terbinafine is an antifungal agent of the allylamine 
group that inhibits ergosterol synthesis. Bahamdan 
et a159 administered terbinafine at a dose between 
250 mglday and 500 mglday for 4 weeks to 27 patients 
with CL. Of the 14 patients who finished the study, 
10 (71.5%) showed a clinical response (either partial 
or complete cure). No side effects were reported. 
Gonzalez-Ruperez et al 6o have also reported the 
successful use of terbinafine in one HIV-positive patient 
with localized CL. 
Miltefosine 
Miltefosine (hexadecylphosphocholine), an agent that 
has been studied in oncologic clinical trials, has 
been used in the therapy of visceral and cutaneous 
leishmaniasis. Jha et a161 administered miltefosine 
loo-150 mg/day for 28 days to 90 Indian patients with 
visceral leishmaniasis, achieving a cure rate of 96%. 
Most recently, Soto et a162 enrolled 72 Colombian 
military personnel with CL into an open-label, rising- 
dose, phase II trial. The cure rate for patients receiving 
133-150 mg/day miltefosine was 94%. Motion sickness 
was seen in 40% of the patients, but it did not interfere 
with their normal duties. 
Immunotherapy 
The roots of immunotherapy lie in the still used ancient 
practice of leishmanization, in which material from an 
active lesion of CL is inoculated into the arm or buttock 
to produce a self-limited lesion in an inconspicuous site. 
Vaccines utilizing killed Leishmania antigens are still 
under investigation. Interferon-y has shown promise 
when combined with Sb in the treatment of visceral, 
mucocutaneous or cutaneous leishmaniasis. Harms 
et a1(j3 conducted a randomized, prospective trial 
comparing intralesional glucantime and intralesional 
interferon-y in 40 patients in Syria. Interferon-y alone 
showed mixed effectiveness. Arana et al64 conducted 
a randomized, double-blind trial of 66 patients in 
Guatemala, comparing meglumine for 20 days, 
meglumine for 10 days, and meglumine for 10 days plus 
interferon-y. Meglumine was given intravenously, and 
interferon or placebo was given subcutaneously (five 
injections in total). Cure rates were 19/21 (90%), 18/20 
(90%), and 22/22 (lOO%), respectively. However, there 
was no statistically significant difference in response 
rates between the three groups. 
CONCLUSION 
The optimal approach to the treatment of CL remains 
a challenge, as systemic therapy is expensive and 
associated with significant toxicities. Definitive recom- 
mendations are hampered by the self-limited nature of 
many cases of CL, and a paucity of rigorously designed 
clinical trials. Sb remains the standard therapy for CL 
that requires treatment, despite its significant toxicities. 
In New World CL, the ability of L. braziliensis to 
progress to mucocutaneous disease necessitates systemic 
therapy. Pentamidine, amphotericin B and azoles are 
also effective as systemic therapy. Local and topical 
therapies, such as topical paromomycin or intralesional 
Sb, may be useful in cases where cosmetic aspects are 
of less concern, particularly in Old World CL, although 
some specific therapeutic modalities may not be widely 
available. Immunotherapy and vaccine development 
represent a promising avenue of continued research. 
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